Email Updates

You are here

Home

28 OCTOBER 2022 VOLUME 24 ISSUE 43

Media Coverage

  • Older People Living With HIV Issue Call to Action

    An international coalition of older people with HIV has issued a new manifesto calling for greater focus on the needs of this group. Initiated at the International AIDS Conference this summer in Montreal and released at the HIV Drug Therapy meeting this week in Glasgow, the manifesto is endorsed by more than 100 HIV/AIDS organizations worldwide.

    October 28, 2022
    General
    POZ Magazine

  • New Approaches to HIV Prevention, Management of Patients With HIV

    In this podcast, Charles Flexner, MD, speaks about the current state of long-acting agents for the management of patients with HIV, HIV prevention and vaccines, and HIV pathogenesis and cure. Dr Flexner also participated in a panel discussion on these topics at ID Week 2022 titled "HIV: State of the ART."

    October 27, 2022
    General
    Consultant 360

  • Omicron Subvariants Are Resistant to Key Antibody Treatments, Putting People With Weak Immune Systems at Risk of COVID

    Emerging omicron subvariants are resistant to key antibody treatments for HIV patients, kidney transplant recipients and other immunocompromised people, making them particularly vulnerable to COVID this winter, the White House warned this week. “With some of the new subvariants that are emerging, some of the main tools we’ve had to protect the immunocompromised like Evusheld may not work moving forward. And that’s a huge challenge,” Dr. Ashish Jha, head of the White House COVID task force, told reporters on Tuesday.

    October 27, 2022
    General
    CNBC

  • New Initiative To Improve HIV Health Outcomes for Black Men Who Have Sex With Men

    The results of a multi-year initiative aimed at improving HIV health outcomes for Black men who have sex with men (MSM) are published in a new Supplement in the peer-reviewed journal AIDS Patient Care and STDs. Black MSM have higher rates of HIV infection than their White counterparts and face a number of comorbidities and challenges that impact their ability to engage or remain in care.

    October 27, 2022
    General
    News Medical

  • Monkeypox Can Be Far More Devastating for Patients With Weak Immune Systems

    Monkeypox is causing devastating outcomes for people with severely weakened immune systems, even as new cases continue to decline in the United States, according to a federal report released Wednesday. At least 10 people hospitalized with monkeypox have died. More than 28,000 cases of monkeypox have been reported since the US outbreak began in May. While the vast majority recover within weeks, some patients with untreated HIV experienced especially dire consequences, such as losing function of their brain or spinal cord, eyes and lungs despite being given antiviral medication.

    October 26, 2022
    General
    Washington Post

  • Most Hospitalized Monkeypox Patients in the US Were HIV-Positive

    Nearly all Americans hospitalized for monkeypox infection had weakened immune systems, most often because of HIV infection, the Centers for Disease Control and Prevention reported on Wednesday. Of 57 hospitalized patients described in the report, 82 percent had HIV More than two-thirds of the patients were Black and nearly one-quarter were homeless, reflecting racial and economic inequities seen in the outbreak overall.

    October 26, 2022
    General
    The New York Times

  • Injectable HIV Drug Widens Options Against HIV Transmission, Says Expert

    Thabo Shole-Mashao spoke to Dr Fareed Abdullah - SAMRC director of the Office of AIDS and TB Research; and medical researcher and chair of SAHPRA - Professor Helen Rees on the approval of Zimbabwe’s HIV prevention drug, and what this means for the treatment of HIV.

    October 26, 2022
    PrEP
    702

  • The Fear Surrounding HIV Is Likely Due to Stigma

    Though Twitter is renowned as a cesspool of negativity, there are times when it inspires positive interactions. I experienced that last July after Donja R. Love―the award-winning Afro-Queer playwright who is living openly with HIV―and I addressed a surge of HIV stigma that had been unleashed by a number of politicians and celebrities.

    October 26, 2022
    General
    TheBody

  • Inside the UK’s Bold, Improbable Plan to End HIV by 2030

    Following up on a national strategy to fight HIV, England’s national medical director recently told The Guardian that the country is on track to eliminate new cases of the virus by 2030. The publication declared that the country was investing its hopes into becoming the first in the world to “defeat” HIV. It would be a groundbreaking achievement, especially for combatting a disease that has no cure. But contrary to popular belief, no new cases does not mean the virus will have been eliminated, in the UK nor elsewhere.

    October 25, 2022
    General
    The Daily Beast

  • It Takes Money to End the HIV Epidemic Among Black Women

    Data show the HIV epidemic affects Black women at strikingly high rates, but Black women working in public health still struggle to access funds for prevention and treatment. Closing that HIV funding gap is one of the goals of ViiV Healthcare — a pharmaceutical company that creates medicines and treatments for people living with HIV. It’s tackling the issue by investing $8 million into Black women-led organizations around the country seeking to transform care related to the virus.

    October 25, 2022
    General
    The Observer

  • HIV Is Not Over, Warns UNAIDS Director for SA After Emergency Meeting

    UNAIDS and its partners this month convened an emergency meeting on HIV prevention. Experts and implementers from around the world joined UNAIDS in South Africa to set targets and put prevention programming into practice. Maverick Citizen spoke to Eva Kiwango, UNAIDS’ country director for South Africa.

    October 25, 2022
    General
    Daily Maverick

  • As HIV Lowers People's Resistance To Many Diseases, Are We Any Close To Developing Its Vaccine?

    Substantial progress has been reported in developing a vaccine that protects against the Human Immunodeficiency Virus (HIV). Two separate papers with the findings were published in the journal 'Immunity'. According to World Health Organization (WHO), HIV attacks the immune system, lowers people's resistance to many diseases and some cancers, and causes immunodeficiency in infected people over time.

    October 23, 2022
    HIV Vaccine
    The Logical Indian

  • Long-Acting Injectable PrEP Effective, Well Tolerated in Patients Regardless of Race

    Studies of long-acting cabotegravir plus rilpivirine demonstrated high efficacy, safety and patient satisfaction regardless of patient race, according to data presented at IDWeek. “Long-acting cabotegravir plus rilpivirine (CAB + RPV LA) administered monthly or every 2 months is the first and only complete long-acting injectable maintenance regimen recommended by treatment guidelines for people living with HIV-1 with virological suppression,” Moti Ramgopal, MD, medical director of the Midway Immunology and Research Center, said during a presentation at IDWeek.

    October 23, 2022
    PrEP
    Infectious Disease News

  • Long-Term Study Results Confirm Benefits of Early HIV Treatment

    Delaying antiretroviral therapy leads to an excess risk of AIDS and serious non-AIDS health problems that can persist for years, even after treatment is started, according to long-term follow-up results from the START trial, presented today at the IDWeek 2022 conference in Washington, DC. Earlier in the HIV epidemic, the best time to start treatment was controversial.

    October 22, 2022
    Treatment
    POZ Magazine

  • ‘No New HIV Cases by 2030’: England Hopes To Become First Country in the World To Defeat Virus

    The NHS believes it will prevent all new cases of HIV by 2030 after signing a series of deals to ensure new medicines are available across England to end regional disparities. People with HIV have access to injectable forms of cabotegravir and rilpivirine, and those with drug-resistant infections will be able to receive fostemsavir after it was approved last week.

    October 22, 2022
    General
    The Guardian

  • Prioritizing Culturally Competent Care, Advocacy, and Access in HIV

    When asked about the “hot” topics in HIV this year, Marwan Haddad, MD, MPH, medical director of the Center for Key Populations at Community Health Center Inc.

    October 22, 2022
    General
    Drug Topics

  • Countering Failures Of Imagination: Lessons We Learnt From Paul Farmer

    Paul Farmer, physician, activist, academic, humanitarian, and teacher died in Rwanda on February 21, 2022. Few people in the field of global health have had a bigger impact than him. After his death, people all over the world took to social media and blogs, and wrote about how his life inspired them. My favorite was this tweet from Arcade Fire, the Canadian rock band: “Paul Farmer changed our lives forever. He showed us how to work harder for others than for yourself. He was the punkest mother fucker WE ever met.”

    October 21, 2022
    General
    Forbes

  • Study: Adherence to PrEP Increases Prevention of HIV

    Pre-exposure prophylaxis (PrEP) helps prevent HIV, with 100 percent efficacy among individuals who adhere well to treatment. However, the lack of access and awareness about PrEP, medication cost, and underestimating HIV risk are all barriers.

    October 21, 2022
    PrEP
    Pharmacy Times

  • Three-Dose Vaccine Prevents HIV Patients Getting Hepatitis B

    Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. During the ACTG A5379 trial (NCT04193189), sponsored by The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), researchers tested 68 HIV-positive adults at 38 sites in the US, South Africa, and Thailand.

    October 21, 2022
    General
    European Pharmaceutical Review

  • Tolerability Drives Most ART Switch Decisions in Patients Living With HIV/AIDS

    There are many factors that can lead to clinicians considering a switch in a patient’s antiretroviral (ART) regimen, including pill burden, weight gain, gastrointestinal intolerance, or complications of comorbid conditions. However, interruption of an ART regimen by switching medications can potentially lead to resistance, rebound of viral loads, and also carries a risk of treatment failure.

    October 21, 2022
    Treatment
    Contagion Live

  • Exciting Alternatives: An Overview of Long-Acting HIV Treatment, Prevention

    An estimated 1.2 million people in the United States live with HIV, of whom 13 percent do not know their status. Although HIV incidence declined overall by 9 percent in 2019, there were still 36,801 new HIV diagnoses. HIV affects everyone, but racial and ethnic minorities and gay, bisexual and other men who have sex with men continue to be disproportionately affected. In the 1980s, the average life expectancy for someone receiving an AIDS diagnosis was approximately 1 year. In 2022, people living with HIV are expected to live a nearly normal life span.

    October 21, 2022
    General
    Infectious Disease News

  • Better Engagement in HIV Care Could Reduce Disparities for Black Gay Men

    Black gay and bisexual men living with HIV currently have a shorter life expectancy than their white peers, but improved engagement in care could help close this gap, according to a modeling study presented at the IDWeek 2022 conference, taking place this week in Washington, DC. “There are significant and unacceptable disparities in HIV care. Black MSM [men who have sex with men] in the United States do not experience the same health outcomes as white MSM,” senior study author Emily Hyle, MD, of Harvard Medical School, said in an IDWeek press release.

    October 21, 2022
    General
    POZ Magazine

  • Washington's HIV Prevention Program Out of Funding in Three Months, Forced to Close

    Washington has run out of funding for its HIV prevention assistance program and its future remains uncertain — despite growing demand. The state Department of Health's program, known as the pre-exposure prophylaxis drug assistance program (PrEP DAP), covers nearly all out-of-pocket expenses for Washingtonians who take HIV prevention medicine, usually a once-a-day pill, or their related lab or doctor visits.

    October 21, 2022
    General
    The Chronicle

Published Research

Announcements